Could a pill reach and fight aggressive brain tumors? early trial hints at possibility
NCT ID NCT05076513
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests the drug niraparib (Zejula) in people with two types of brain cancer: newly diagnosed glioblastoma and recurrent glioma with specific genetic changes (IDH mutation and ATRX loss). The study first checks if the drug reaches the tumor tissue, then gives it to those who show a response, combined with radiation or alone. Up to 42 participants will be enrolled to see if niraparib can slow tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Niraparib (Zejula), a cancer drug taken as a pill
- What this could lead to
- If successful, this could point toward a new treatment option for aggressive brain cancers like glioblastoma and certain recurrent gliomas.
- What could go wrong
- This is a very early (Phase 0) trial with only 42 participants, so it is too soon to know if niraparib will be effective or safe for these brain cancers. The drug may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GBM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- Can adding lenvatinib to standard care outsmart a tough brain cancer?
- A simple lotion duo may shield skin from Tumor-Treating fields